• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Verastem

edit

Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.

Recent Milestones

edit

• 
  Verastem received $20M in Series C funding. (11/11/11)
  Posted 11/11/11 at 6:29pm via masshightech.com
• 
  Verastem received $32M in Series B funding. (7/14/11)
  Posted 7/14/11 at 5:12pm via masshightech.com
• 
  Verastem — Henri Termeer, chairman and CEO of Genzyme Corp. has been named to the board of biopharmaceutical Verastem Inc. (6/13/11)
  Posted 6/14/11 at 5:40am via masshightech.com
• 
  Verastem received $16M in Series A funding. (11/16/10)
  Posted 11/16/10 at 6:57pm via finsmes.com
• 
  Verastem added Christoph Westphal as Chairman.
  Posted 11/16/10 at 6:57pm
• 
  Verastem added Satish Jindal as President and COO.
  Posted 11/16/10 at 6:57pm

Videos

Screenshots

edit

Sources

1. Verastem Closes $16M Series A Financing (finsmes.com) [edit]
2. Verastem rounds up $32M in second funding (masshightech.com) [edit]
3. Verastem, with IPO planned, raises $20M in funding (masshightech.com) [edit]
Former Genzyme CEO Termeer named to Verastem board (masshightech.com) [edit]